Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 77.20% | 4.12% | 24.77% | 19.36% | -4.44% |
| Total Depreciation and Amortization | 1.04% | -5.88% | -6.42% | -0.91% | -0.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30,050.00% | -99.29% | -66.55% | 72.65% | -15.08% |
| Change in Net Operating Assets | -69.64% | -423.32% | 135.38% | -246.85% | 839.91% |
| Cash from Operations | 22.32% | -79.58% | 50.88% | -27.04% | 12.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | 1,600.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 200.00% | -202.79% | -85.04% |
| Cash from Investing | -- | -- | 200.90% | -202.73% | -85.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 102.96% | -58.38% | 1,303.67% | -82.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 300.00% |
| Cash from Financing | -32.00% | 110.52% | -59.87% | 1,287.24% | -82.58% |
| Foreign Exchange rate Adjustments | -- | -- | -200.00% | 200.00% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -241.03% | -137.40% | 151.63% | 70.53% | -188.36% |